The purpose of this study is to find out whether the study drug, LY3537982, is safe and
effective in cancer patients who have a specific genetic mutation (KRAS G12C). Patients must
have already received or were not able to tolerate the standard of care, except for specific
groups who have not had cancer treatment. The study will last up to approximately 4 years.
The purpose of this study is to assess the efficacy and safety of co-formulated
pembrolizumab/quavonlimab versus other treatments in participants with MSI-H or dMMR
Metastatic Stage IV Colorectal Cancer.
Eben Rosenthal, M.D.
- Professor and Chair, Department of Otolaryngology–Head and Neck Surgery
- Co-Leader, Translational Research and Interventional Oncology Research Program
- Guy M. Maness Professor of Otolaryngology
- Barry and Amy Baker Chair in Laryngeal, Head and Neck Research
- Professor, Department of Pathology, Microbiology and Immunology
Eben Rosenthal, M.D.
- Professor and Chair, Department of Otolaryngology–Head and Neck Surgery
- Co-Leader, Translational Research and Interventional Oncology Research Program
- Guy M. Maness Professor of Otolaryngology
- Barry and Amy Baker Chair in Laryngeal, Head and Neck Research
- Professor, Department of Pathology, Microbiology and Immunology
e.rosenthal@vumc.org
Research Program
Research Description
This phase II trial studies whether adding pembrolizumab to olaparib (standard of care) works better than olaparib alone in treating patients with pancreatic cancer with germline BRCA1 or BRCA2 mutations that has spread to other places in the body (metastatic). BRCA1 and BRCA2 are human genes that produce tumor suppressor proteins. These proteins help repair damaged deoxyribonucleic acid (DNA) and, therefore, play a role in ensuring the stability of each cells genetic material. When either of these genes is mutated, or altered, such that its protein product is not made or does not function correctly, DNA damage may not be repaired properly. As a result, cells are more likely to develop additional genetic alterations that can lead to some types of cancer, including pancreatic cancer. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Olaparib is an inhibitor of PARP, a protein that helps repair damaged DNA. Blocking PARP may help keep tumor cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy. The addition of pembrolizumab to the usual treatment of olaparib may help to shrink tumors in patients with metastatic pancreatic cancer with BRCA1 or BRCA2 mutations.
